| INTRODUCTION
Acid-related diseases, such as gastro-oesophageal reflux disease (GERD), and gastric and duodenal ulcers, have high prevalence and chronic nature. 1, 2 The pathophysiology of gastro-oesophageal reflux is influenced by genetic, anatomic and neurogenic factors, as well as lifestyle-related factors, such as poor diet and smoking habits. 3 Treatment of GERD includes lifestyle modifications, antacids, histamine 2-receptor blockers, proton pump inhibitors (PPIs), promotility agents and anti-reflux surgery. The most common treatment method is using PPIs, which rapidly alleviates symptoms and resolves oesophagitis in many GERD patients. 4 However, PPIs have a limited gastric acid suppression effect, as there were no responses in up to 40% of GERD patients when they
were administered a standard PPI dose once daily. 5 Moreover, in patients who responded well to PPIs, the maximum effect was observed only after 3-5 days. PPIs' slow onset of action is caused by their short half-lives in the plasma and irreversible covalent disulphide bonding with H + ,K + -ATPase, the efficacy of which requires an acidic environment. 6, 7 In addition, patients with erosive oesophagitis often fail treatment even after 8 weeks of PPI therapy. In fact, completely healed patients may show relapse after receiving PPI maintenance therapy. 2 Another limitation of PPIs is nocturnal acid breakthrough, and it is recommended to administer them on an empty stomach as they are pro-drugs which should be activated by the acidic environment. 8, 9 Additionally, because of the involvement of the CYP2C19 genetic polymorphism in its metabolism, the interindividual variability of its effect is large, causing it to not always exhibit a sufficient level of drug efficacy in every population. Furthermore, the study by Lazarus et al (2016) suggested that chronic use of PPIs may lead to impaired renal function. 10 Particularly, in acute kidney injury, PPI use is associated with acute interstitial nephritis and it is an independent risk factor for chronic kidney disease. 9 To overcome the limitations of PPIs, a novel class of acid suppressing drugs, potassium-competitive acid blockers (P-CABs), has been developed. P-CABs inhibit H + ,K + -ATPase by reversible potassium-competitive ionic binding with no acid activation required, and have a relatively longer half-life than PPIs. 2 In addition, P-CABs inhibit gastric acid secretion within a short period of time and have similar effects at both single and multiple doses. 11 Therefore, P-CABs are expected to have the advantages of faster onset of action, fewer night acid breakthroughs, and lower effect of CYP2C19 polymorphisms than PPIs. 12, 13 DWP14012 is a novel P-CAB that is under clinical development by Daewoong Pharmaceutical Co., Ltd (Seoul, Korea). In preclinical study, DWP14012 inhibited acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion was equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models. Based on these findings, a first-in-human trial was performed to evaluate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of DWP14012 compared with those of esomeprazole, an active com- The doses of 10-320 mg per 60 kg body weight was determined based on the no-observed-adverse-effect level (NOAEL) established in a preclinical toxicity studies in rats and dogs (human equivalent of 5.2-5.5 mg/kg per day). The starting dose, 10 mg, was set at 1/30 of the NOAEL. The effect of food on the PKs and PDs of DWP14012 was evaluated in the 160 mg dose group, as this dose was predicted during study planning to show maximum efficacy (based on preclinical studies), by administering the study-drug at fasting and high-fat-fed states in periods 1 and 2, respectively, with 7 days of washout between the periods.
In the MAD study, a total of 48 subjects were randomly assigned to receive once daily oral doses of 20, 40, 80 or 160 mg DWP14012, 40 mg esomeprazole or placebo in fasted state for 7 days at a ratio of 8:2:2.
The safety and tolerability of the drug were evaluated by monitoring the adverse events (AEs) and vital signs, electrocardiograms (ECGs), physical examinations and clinical laboratory tests. In the MAD study, microRNA-122 (miR-122), a liver injury biomarker, was evaluated alongside the total serum levels of liver enzymes and total bilirubin to assess drug-induced liver injury. 14, 15 To evaluate the PDs of DWP14012, 24 hours gastric pH monitoring was performed using a Digitrapper pH 400 recorder (Medtronic, Dublin, Ireland). Serial serum gastrin concentrations were also assessed a day before studydrug (baseline) and after the study-drug administration in the SAD study, whereas in the MAD study, they were assessed at baseline, after the first dose, and after the last dose. PK parameters were evaluated through the DWP14012 concentrations in serial plasma and urine samples. 
| Determination of the DWP14012 concentration in plasma and urine samples
For the PK analysis, serial plasma and urine samples were collected.
In the SAD study, plasma samples were collected using sodium hep- 
| PK analysis
The following PK parameters of DWP14012 were analysed through non-compartmental analysis using Phoenix WinNonlin software ver- All data are presented as the number of subjects (%).
under the concentration-time curve (AUC) from 0 to the last measurable time (AUC last ), the AUC from 0 to infinity (AUC infinite ), the AUC during the dosing intervals (AUC s ), the terminal half-life (t 1/2 ), the apparent clearance (CL/F), the renal clearance (CL R ) and the urinary excreted fraction (fe). The accumulation ratio was calculated as the ratio of AUC s after the administration of the seventh dose in comparison with that after the administration of the first dose.
| Measurement of serum microRNA-122
Total serum RNA was extracted using a miRNeasy Serum/Plasma kit (Qiagen, Hilden, Germany) according to the manufacturer's manual. and elongation for 30 seconds at 70°C.
| Statistical analysis
All data were summarised using descriptive statistics. A mixedeffect model was used to compare miR-122 levels after study-drug administration with its baseline levels. (GMR) of PD and PK parameters were calculated and its 2-sided 90% confidence interval (CI) were calculated for the fed state to fasting state. With regard to the C max and AUC s of DWP14012, dose proportionality was analysed using a power model with the following equations:
If the 95% CI for the regression parameter (b 1 ) included 1, the C max and AUC s were regarded as dose proportional.
The relationship between AUC s and %Time pH ≥4 was evaluated in the MAD study using the sigmoid E max model. PK and PD data after the first and last doses were used for the analysis. Maximum effect (E max ), Hill coefficient (Υ), baseline effect (E 0 ), half the maximum effect (EC 50 ) and 90% of the maximum effect (EC 90 ) were analysed using Phoenix WinNonlin software version 1.4 (Certara).
All statistical analyses were 2-sided with 5% level of significance, unless otherwise stated, and were performed using SAS Version 9.3 (SAS Institute, Inc., Cary, NC, USA).
| RESULTS

| Study population
A total of 122 subjects were enrolled in the study, and 120 subjects were administered DWP14012, esomeprazole or placebo at a ratio of 8:2:2 (n = 72 in the SAD study and n = 48 in the MAD study). The | 211 safety, tolerability and PD were analysed for the 120 subjects who received DWP14012, esomeprazole, or placebo, whereas PK analysis was performed on the 80 subjects who received DWP14012.
The demographic characteristics of the total 122 subjects were within the following ranges: 20-50 years (age), 55. 
| Safety and tolerability
Single-and multiple-dose administrations of DWP14012 were generally well tolerated by the subjects. During the SAD study, 28 treatment-emergent AEs (TEAEs) were reported by 18 subjects. After the single administration of the study-drug in the fed state, 4 TEAEs were reported by 3 subjects. In the MAD study, a total of 35 TEAEs were reported by 20 subjects. The cases were determined to be associated with DWP14012 and are reported in Table 1 . Among the TEAEs, 5
DWP14012-related AEs were reported in the SAD study, including epigastric discomfort, dyspepsia, nausea and headache, whereas 11 DWP14012-related AEs were reported in the MAD study, including gastrointestinal disorders (abdominal discomfort, abdominal distension, abdominal pain and oesophageal pain), skin and subcutaneous tissue disorders (pruritus, rash and skin exfoliation), headache, lethargy, increased blood creatinine phosphokinase and agitation. In the food effect cohort of the SAD study, 3 TEAEs, including vomiting and headache, were reported by 2 subjects and considered to be associated with DWP14012. All TEAEs were mild in intensity and were spontaneously resolved. No serious adverse events were observed in this study. No other clinically significant changes were observed in the clinical laboratory tests, vital signs, ECGs, or physical examinations.
The potential liver toxicity of DWP14012, evaluated with the total serum levels of liver enzymes, total bilirubin and miR-122, was not higher than that of placebo after multiple oral administrations. Clinically significant abnormalities in liver enzyme and total bilirubin levels were not reported in this study. Mean liver enzyme levels were within the reference range throughout the study. The observed increase in liver enzyme and total bilirubin levels was neither dose-nor time- higher level of miR-122 than the baseline level on the last dosing day (day 7, P = 0.029), but that increment was not statistically significant at 48 hours after the last dosing day (day 9, P = 0.750; Figure 2 ).
| Pharmacodynamics
DWP14012 showed rapid and sustained suppression of gastric acid secretion for 24 hours after single and multiple oral administrations. In the SAD study, the mean gastric pH of subjects who received 80, 160 and 320 mg DWP14012 reached more than 4 within 2 hours after drug administration and was sustained during the remaining monitoring times (Figure 3 ). In the MAD study, the mean gastric pH of subjects who received 80 and 160 mg DWP14012 was more than 4 during the 24 hours (Figure 3) . The mean gastric pH-time profile of subjects who received 40 mg DWP14012 was similar to those who received esomeprazole 40 mg (Figure 3) . 
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The gastric pH increased as the dose of DWP14012 increased ( Figure 4 , Table 2 ). %Time pH ≥4 for esomeprazole in the night-time was lower than that of the daytime, whereas the groups that received The serum gastrin levels increased after single and multiple oral administrations of DWP14012 and esomeprazole ( Figure 5 ).
The serum gastrin levels observed in the subjects who received 40 mg DWP14012 were similar to those of who received 40 mg esomeprazole.
| Pharmacokinetics
In the SAD study, the plasma concentrations of DWP14012 reached The plasma concentration of DWP14012 was not significantly changed by the high-fat diet provided before the study-drug administration ( Figure 6 , Table 3 ). The GMR of the fed state to fasting state for C max and AUC were 1.06-1.09 and its 90% CI fell between the conventional bioequivalence ranges of 0.8-1.25.
In the MAD study, DWP14012 did not significantly accumulate in the plasma after once daily administration of study-drug ( Figure 6 , Table 3 ). The mean accumulation ratio was 0.93-1.48. The time to reach C max,ss at steady state (T max,ss ) ranged from 1.50 to 5.00 hours and the mean t 1/2 ranged from 7.5 to 9.5 hours, similar to those of the SAD study. The plasma concentration of DWP14012 increased dose proportionally across the 20-160 mg dose range after multiple oral administrations. The 95% CIs of the slope of the log-transformed C max, ss and AUC s included 1.0 (0.86-1.31 and 0.89-1.31, respectively), and is thus regarded as dose proportional. The mean urinary excreted fraction of unchanged DWP14012 was <1% in every dose group.
| Relationship between pharmacokinetics and pharmacodynamics
A clear exposure-response correlation was observed after single and multiple oral administration of DWP14012 (Figure 7) . The E max , EC 50 and EC 90 were 80.5%, 437 hÁl/L and 1244 hÁl/L, respectively. There were statistically significant correlations between the T A B L E 2 Pharmacodynamic parameters after single and multiple oral administrations of DWP14012, esomeprazole or placebo All data are presented as the mean AE SD.
AUC parameters and the %Time pH ≥4. The gastric pH parameters increased as the PK parameters were increased. Based on visual assessments, the maximum PD effect was more than the 2000 hÁl/L of AUC infinite and those drug exposures were observed in subjects receiving 160 mg or higher DWP14012 in the SAD study. The maximum PD effect was more than the 1000 hÁl/L of AUC s in subjects receiving 80 mg or higher DWP14012 in the MAD study.
| DISCUSSION
This trial was a first-in-human, Phase 1 clinical study to investigate the safety/tolerability, PD and PK characteristics of DWP14012 tablets after single and multiple administrations to healthy subjects.
DWP14012 was safe and well tolerated at a single dose of up to 320 mg and at multiple doses of up to 160 mg for 7 days in healthy male subjects, based on the resulting adverse events, clinical laboratory tests, vital signs, ECGs and physical examinations.
The serum gastrin level increased after DWP14012 administration and such an increase was also observed with P-CABs including vonoprazan ( Figure 5 ). 2, 16 However, the gastrin-increasing effect of DWP14012 was lower than that of vonoprazan, 2 and returned within normal range in all subjects after 48 hours of the last dose in the MAD study.
Hepatotoxicity of the P-CAB formulation should be carefully evaluated because the development of the prototype P-CAB SCH28080 was discontinued due to hepatotoxicity and liver function abnormalities in 0.2% of patients in vonoprazan clinical trials. 17, 18 After once daily oral treatment with DWP14012 for 7 days, the total serum levels of liver enzymes and bilirubin were stable throughout the study (Figure 1 ). Furthermore, in subjects who received DWP14012, the miR-122 levels were also stable throughout the study, and the mean miR-122 fold changes were comparable with those of subjects who received placebo ( Figure 2 ). We concluded that the potential liver toxicity of DWP14012 was not higher than that of placebo, based on the miR-122, liver enzyme and total bilirubin test results. showed similar PD effect to that of esomeprazole 40 mg, and DWP14012 80 mg is expected to be around the ED 90 . Consequently, the lowest expected effective dose in acid-related disease is considered to be in the range of DWP14012 40-80 mg.
Although the plasma concentration of DWP14012 increased in more than a dose-proportional manner after a single dose, the plasma concentration of DWP14012 increased dose proportionally across 20-160 mg dose range after multiple doses. In the MAD study, DWP14012 did not significantly accumulate in the plasma beyond the concentration achieved with the initial dose. The primary elimination pathway of DWP14012 in humans is via a nonrenal route (Table 3) , and it is predicted that liver or gut metabolism plays an important role in the absorption and elimination of DWP14012.
The high-fat diet given before drug administration did not cause clinically significant effects on the PK and PD of DWP14012. Therefore, in further clinical studies, DWP14012 can be administered regardless of food intake to treat gastric acidrelated diseases.
In conclusion, DWP14012 is safe and well tolerated in the healthy male subjects, and the study results justify further investigations of DWP14012 in patients with acid-related disorders.
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F I G U R E 7 Pharmacokineticpharmacodynamic relationships of DWP14012. The percentage of time that gastric pH was ≥4 over 24 h is plotted vs AUC s after the first and last dose in the multiple-ascending dose study
